Breaking News
June 21, 2018 - People with severe obesity constantly try to reduce or control their weight
June 21, 2018 - Recovery and Treatment | NIH MedlinePlus the Magazine
June 21, 2018 - ‘Hidden’ driver discovered that helps prime the anti-tumor immune response
June 21, 2018 - Groundbreaking discovery could be key to preventing cancer metastasis
June 21, 2018 - Impulse control disorders found to be more common in people taking Parkinson’s drugs
June 21, 2018 - Study finds possible link between Type 2 diabetes and common white pigment
June 21, 2018 - Most emergency department patients wish to be involved in medical decision-making
June 21, 2018 - Study highlights growing problem of ‘iPad neck’ among young adults and women
June 21, 2018 - UT Southwestern scientists identify gene mutation linked with perplexing brain condition
June 21, 2018 - New study sheds light on role of vitamin D in healthy pregnancy
June 21, 2018 - Teva Provides Update on Clinical Trial of Fremanezumab for Use in Chronic Cluster Headache
June 21, 2018 - Unlocking the secrets of HIV’s persistence
June 21, 2018 - New guidelines recommend newborns with Down’s syndrome to receive leukemia test
June 21, 2018 - BetterYou’s new Magnesium Bone Lotion helps maximize bone health
June 21, 2018 - UH scientist receives grant to examine understudied part of glaucoma
June 21, 2018 - Lifestyle intervention could normalize unhealthy behaviors that lead to cancer, chronic disease
June 21, 2018 - Combining two anti-malarial vaccines could greatly reduce number of infections
June 21, 2018 - By 2030, prostate and lung cancers expected to be most common cancers among HIV population
June 21, 2018 - Researchers evaluate patient satisfaction and well-being after breast reconstruction
June 21, 2018 - Combining stem cell technology and artificial intelligence to diagnose genetic cardiac diseases
June 21, 2018 - Monash study reveals why older people have reduced immune responses to cancer therapy
June 21, 2018 - Researchers develop new microscope system that can image living tissue in real time
June 21, 2018 - Long-term estrogen therapy alters microbial composition and activity in the gut
June 21, 2018 - Study points to dangers of feeding non-dairy drink to infants
June 21, 2018 - Cannabis Use Linked to Psychosis Symptoms in Adolescents
June 21, 2018 - Inadequate sleep could cost countries billions
June 21, 2018 - Inhibiting epigenetic proteins with drugs could prevent development of breast cancer
June 21, 2018 - Study identifies factors that contribute to vaginal dryness
June 21, 2018 - Researchers employ nucleotide-based gene silencing to mitigate common ataxia
June 21, 2018 - New tool determines best treatment plan for adults with severe asthma
June 21, 2018 - Identifying gene variants that contribute to ovarian reserve may improve female fertility
June 21, 2018 - Religious involvement has no significant effect on misuse of prescription opioids, study finds
June 21, 2018 - Researchers characterize key signaling network that drives growth of triple negative breast cancers
June 21, 2018 - AHA: Big Weight Gain in 1st Pregnancy Could Boost Preeclampsia Risk
June 21, 2018 - How vaping helps even hardened smokers quit
June 21, 2018 - Gaming disorder an official disease condition says WHO
June 21, 2018 - Oxygen consumption in human BAT increases after a meal, shows research
June 21, 2018 - Research finds addictions to be diseases of the brain, not criminal behavior or personality disorders
June 21, 2018 - New study is testing safety and efficacy of glycoside in breaking up kidney stones
June 21, 2018 - Biosimilar competition may offer hope for cheaper, better psoriasis treatments in the future
June 21, 2018 - Cells form cage-like structures that trap viruses
June 21, 2018 - Wound protector use linked to significant reduction in surgical site infection
June 21, 2018 - African Americans and Latinos are more likely to be at risk for depression than Whites
June 21, 2018 - Genome study presents new way to track historical demographics of US populations
June 20, 2018 - Study sheds light on the early stages of tumorigenesis
June 20, 2018 - Quick adoption of new diagnostic tests could help NHS to save nearly £7 billion
June 20, 2018 - Mayo Clinic researchers find genetic mutations that increase person’s risk for pancreatic cancer
June 20, 2018 - Chemists invent new method for remote chiral induction
June 20, 2018 - Methadone or buprenorphine associated with reductions in opioid related mortality
June 20, 2018 - New simulation approach predicts efficacy of HIV-prophylaxis medications
June 20, 2018 - Rhythm Pharmaceuticals Completes Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Evaluating Setmelanotide in Rare Genetic Disorders of Obesity
June 20, 2018 - Threat of malaria left its mark on the immune system in people with African ancestry
June 20, 2018 - Recent-onset type 2 diabetes may be early expression of pancreatic cancer
June 20, 2018 - Why are vaccines less effective in the developing world?
June 20, 2018 - Study opens new window into cellular events that occur in the brain during absence seizures
June 20, 2018 - Humana and Walgreens to provide easier access to primary care and other services for seniors
June 20, 2018 - ANU research could help find life in Mars and other planets
June 20, 2018 - Multidisciplinary Human-Focused Research
June 20, 2018 - ‘Mind-minded’ parents contribute greatly to development of infants’ emotion regulation capacity
June 20, 2018 - New study finds increase in use of alternative medicines among children
June 20, 2018 - Forgetting plays a positive role in learning, research suggests
June 20, 2018 - Elevated NT-proBNP Found to Up Cardiovascular Risk in T2DM
June 20, 2018 - Genetics Home Reference: White-Sutton syndrome
June 20, 2018 - Canadian team reports success in transplanting hepatitis C organs
June 20, 2018 - Separating migrant children from parents at US border tantamount to child abuse
June 20, 2018 - Study finds more information about how gene linked to ASD affects the brain
June 20, 2018 - Researchers develop portable monitor to detect dangerous drop in white blood cells
June 20, 2018 - Floppy eyelids linked to sleep apnea
June 20, 2018 - Can-Fite provides update on Phase II clinical trial with drug candidate Namodenoson
June 20, 2018 - KIYATEC enrolls first patients with solid tumors in clinical study of its EV3D drug response assay
June 20, 2018 - Study finds growing support to allow pharmacists to write prescriptions
June 20, 2018 - Malnutrition could have major health implications on patients’ surgical outcomes, shows research
June 20, 2018 - LabConnect collaborates with Symphony to support clinical research industry
June 20, 2018 - Italian innovative SME receives 2.5 million Euro from RedSeed Ventures
June 20, 2018 - AHA: Kids Can Drown Quickly and Silently, So Prevention Is Key
June 20, 2018 - Continuous glucose monitors proven cost-effective, add to quality of life for diabetics
June 20, 2018 - Researchers use droplet-sized ‘miniecosystems’ to test therapeutic potential of molecules
June 20, 2018 - New approach could provide objective and easy-to-obtain measure of dietary adherence
June 20, 2018 - Dual-therapy approach can help boost motor recovery in stroke victims
June 20, 2018 - ‘Miracle treatment’ long-term success for babies with diabetes
FDA approves novel enzyme therapy for adults with rare and serious genetic disease

FDA approves novel enzyme therapy for adults with rare and serious genetic disease

image_pdfDownload PDFimage_print

The U.S. Food and Drug Administration today approved Palynziq (pegvaliase-pqpz) for adults with a rare and serious genetic disease known as phenylketonuria (PKU). Patients with PKU are born with an inability to break down phenylalanine (Phe), an amino acid present in protein-containing foods and high-intensity sweeteners used in a variety of foods and beverages. Palynziq is a novel enzyme therapy for adult PKU patients who have uncontrolled blood Phe concentrations on current treatment.

“This is a novel enzyme substitution therapy that helps address a significant unmet need in PKU patients who have been unable to control their blood Phe levels with current treatment options,” said Julie Beitz, M.D., director of the Office of Drug Evaluation III in FDA’s Center for Drug Evaluation and Research. “This new approval demonstrates our commitment to approving advancements in treatment that will give patients living with PKU different options for care.”

PKU affects about 1 in 10,000 to 15,000 people in the United States. If untreated, PKU can cause chronic intellectual, neurodevelopmental and psychiatric disabilities. Lifelong restriction of phenylalanine intake through the diet is needed to prevent buildup of Phe in the body, which can cause long-term damage to the central nervous system.

The safety and efficacy of Palynziq were studied in two clinical trials in adult patients with PKU with blood phenylalanine concentrations greater than 600 µmol/L on existing management. Most PKU patients in the Palynziq trials were on an unrestricted diet prior to and during the trials. The first trial was a randomized, open-label trial in patients treated with increasing doses of Palynziq administered as a subcutaneous injection up to a target dose of either 20 mg once daily or 40 mg once daily. The second trial was an 8-week, placebo-controlled, randomized withdrawal trial in patients who were previously treated with Palynziq. Patients treated with Palynziq achieved statistically significant reductions in blood phenylalanine concentrations from their pre-treatment baseline blood Phe concentrations.

The most common adverse events reported in the Palynziq trials included injection site reactions, joint pain, hypersensitivity reactions, headache, generalized skin reactions lasting at least 14 days, pruritus (itchy skin), nausea, dizziness, abdominal pain, throat pain, fatigue, vomiting, cough and diarrhea. Hypersensitivity reactions occurred in most patients, likely due to formation of antibodies to the product.

The most serious adverse reaction in the Palynziq trials was anaphylaxis, which occurred most frequently during upward titration of the dose within the first year of treatment. Because of this serious risk, the labeling for Palynziq includes a Boxed Warning and the product is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Palynziq REMS Program. Notable requirements of the Palynziq REMS Program include the following:

  • Prescribers must be certified by enrolling in the REMS program and completing training
  • Prescribers must prescribe auto-injectable epinephrine with Palynziq
  • Pharmacies must be certified with the program and must dispense only to patients who are authorized to receive Palynziq
  • Patients must enroll in the program and be educated about the risk of anaphylaxis by a certified prescriber to ensure they understand the risks and benefits of treatment with Palynziq
  • Patients must have auto-injectable epinephrine available at all times while taking Palynziq

The FDA granted approval of Palynziq to BioMarin Pharmaceutical Inc.

Source:

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm608835.htm

Tagged with:

About author

Related Articles